Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint
(NYSE: TAK) Delayed: 18.91 -0.14 (0.73%)
Previous Close $19.05    52 Week High $0.55 
Open $18.80    52 Week Low $0.55 
Day High $19.01    P/E N/A 
Day Low $18.80    EPS $-0.20 
Volume 2,960,710